Dr. Jennifer Brown on Mutations and Targets in CLL

Jennifer Brown, MD, PhD
Published: Monday, Apr 01, 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia (CLL).

Brown says that often when considering targeted therapies, physicians and researchers think to look for a kinase that possesses a mutation that makes it active all the time. Brown provides the examples of EGFR inhibitors that work better in patients with lung cancer who have EGFR mutations or inhibiting BCR-ABL activating mutations in chronic myeloid leukemia.

In CLL, there are no mutations in these tyrosine kinases, but there is chronic activation of the pathway, which could be attributed to the nature of the disease or the surrounding cells in the environment.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia (CLL).

Brown says that often when considering targeted therapies, physicians and researchers think to look for a kinase that possesses a mutation that makes it active all the time. Brown provides the examples of EGFR inhibitors that work better in patients with lung cancer who have EGFR mutations or inhibiting BCR-ABL activating mutations in chronic myeloid leukemia.

In CLL, there are no mutations in these tyrosine kinases, but there is chronic activation of the pathway, which could be attributed to the nature of the disease or the surrounding cells in the environment.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x